Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121329 · ClinicalTrials.gov registry record · NA
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions
A NA study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT00121329: Completed NA study, sponsored by Oregon Health and Science University.
NCT00121329 is a NA study that has completed, run by Oregon Health and Science University. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121329, a NA study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some studies at decreasing patient pain associated with these intrauterine procedures at an anesthetic concentration of at least 2%. Based on this evidence, we hypothesized that an intrauterine lidocaine infusion may reduce patient pain during first trimester abortions.
Interventions
- DRUG Intrauterine lidocaine infusion 4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Est. Completion | 2004-12 |
| Phase | NA |
What the finished NCT00121329 record still lists
NCT00121329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Intrauterine lidocaine infusion 4% is the first listed.
NCT00121329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00121329 about?
NCT00121329 is a clinical study titled "4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions". Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some s...
What is the current status of trial NCT00121329?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00121329?
The interventions under investigation include: Intrauterine lidocaine infusion 4% (DRUG).
Who is sponsoring clinical trial NCT00121329?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00121329's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts